CAR T-Cell Therapy Market

The CAR T-cell therapy market is projected to reach USD 13.56 billion by 2031 from USD 6.78 billion in 2026, at a CAGR of 14.9% during the forecast period. The growth of the CAR T-cell therapy market is propelled by growing prevalence of cancer and technological advancements in the CAR T-cell therapy market. Additionally, rising investment and funding for CAR T-cell therapy development is further likely to drive the market growth.

The global CAR T-cell therapy market is consolidated with top players such as Bristol-Myers Squibb Company (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Johnson & Johnson (US), CARsgen Therapeutics Holdings Limited (China),  IASO Biotherapeutics (China), JW (Cayman) Therapeutics Co. Ltd (China), ImmunoAct (India), Autolus Therapeutics (UK), Allogene Therapeutics (US), Cartesian Therapeutics, Inc. (US), Guangzhou Bio-gene Technology Co., Ltd (China) and Wugen (US). The market players have adopted various strategies such as new product launches, acquisitions, agreements, collaborations, partnerships, and geographical expansions to strengthen their position in the global CAR T-cell therapy market.  

To know about the assumptions considered for the study download the pdf brochure

Johnson & Johnson (US)

Johnson & Johnson is a global healthcare company engaged in the discovery, development, and commercialization of innovative medicines and medical technologies. In the CAR T-cell therapy market, the company has built its presence through CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed autologous CAR T-cell therapy for relapsed or refractory multiple myeloma, developed and commercialized through its long-standing collaboration with Legend Biotech.

Bristol-Myers Squibb Company (US)

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering and developing therapies across oncology, hematology, immunology, cardiovascular disease, and neuroscience. It is one of the leading players in the CAR T-cell therapy market, supported by strong brand equity and a robust product portfolio. The company continues to invest heavily in R&D to advance new therapeutic innovations and sustain its leadership position. The company’s key commercialized CAR T therapies include ABECMA (idecabtagene vicleucel) and BREYANZI (lisocabtagene maraleucel).

Gilead Sciences, Inc. (US)

Gilead Sciences is a research-driven biotechnology company engaged in the discovery, development, and commercialization of innovative medicines. The company markets two US FDA-approved CAR T-cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel). Gilead’s acquisition of Kite Pharma and the subsequent commercialization of Yescarta established a strong footprint in the CAR-T space. Ongoing collaborations with academic institutions, biotech companies, and healthcare providers further strengthen its R&D and clinical capabilities by enabling access to novel technologies and accelerating clinical development. For example, in November 2023, Arcellx and Gilead expanded their collaboration for Arcellx’s CAR-T program targeting multiple myeloma.

Novartis AG (Switzerland)

Novartis AG is a healthcare company that develops novel therapies for various therapeutic areas, including cardiovascular, renal, metabolic, immunology, neuroscience, and oncology. The company’s products are significant contributors to the CAR T- cell therapy market. Novartis gained an early foothold in the CAR T-cell therapy market with the FDA approval of Kymriah (tisagenlecleucel) in 2017, becoming the first approved CAR T therapy for B-cell precursor Acute Lymphoblastic Leukemia (ALL). This approval enabled Novartis to establish strong brand recognition and credibility in the field. The company also has a strong geographic presence with distribution channels across North America, Europe, Asia Pacific, Latin America, and Africa.

Related Reports:

CAR T-Cell Therapy Market by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), Region, Competitive Landscape - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]